NASDAQ
1.25USD
-0.13 (-9.42%)
We have scored 5 news catalysts on Lunai Bioworks Inc. (LNAI) over the past 12 months. The biggest single-day move next to one of them came Feb 9, 2026, when LNAI closed +24.7%: “Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data”. Coverage across the window leans positive (average ticker sentiment +0.66). Most of the impact sits in short squeeze potential and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
6M
P/E
—
EPS
—
Beta
0.34
52W range
1.208-13.28
Day range
1.24–1.46
Open
1.46
Prev close
1.38
Volume
119.9K
Avg volume
705.4K
Dividend
0.00
IPO
2025-09-30
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Lunai Bioworks Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for LNAI: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."
